The European Drug-Drug Interaction (EuroDDI) Study Protocol: A Cross-Country Comparison of Drug-Drug Interaction Prevalence in the Older Community-Dwelling Population

Overview

Journal Pharmacoepidemiol Drug Saf

Publisher Wiley

Date 2025 Jan 8

PMID 39777812

Authors

John E Hughes

Enrica Menditto

Sara Mucherino

Valentina Orlando

Aida Moreno-Juste

Antonio Gimeno-Miguel

Beatriz Poblador-Plou

Mercedes Aza-Pascual-Salcedo

Francisca Gonzalez-Rubio

Ignatios Ioakeim-Skoufa

Kathleen Bennett

Caitriona Cahir

Affiliations

Soon will be listed here.

Abstract

Background: Drug-drug interactions (DDIs), highly prevalent amongst the elderly, can lead to avoidable medication-related harm. Cardiovascular and central nervous system (CNS) drugs are commonly implicated. To date, there is no consensus on how to measure DDIs, making comparisons across countries challenging.

Objective: To (i) establish a common data model (CDM) to measure DDI prevalence in the older (aged ≥ 70 years) community-dwelling population of three European countries and (ii) compare and describe cardiovascular and CNS DDI prevalence rates across these countries.

Methods: This cross-country study will apply a harmonised method of DDI identification and analysis using the WHO ATC classification system and national pharmacy claims data from three European countries (Ireland, Italy, Spain). Patients aged ≥ 70 years dispensed ≥ 2 medications during 2016 will be identified from each country's national database. 'Severe' cardiovascular and CNS DDIs (i.e., may result in a life-threatening event/permanent detrimental effect) will be identified using the British National Formulary and Stockley's Drug Interactions. Two separate lists of 'severe' DDIs, per medications reimbursed, will be applied to each database: (i) DDIs relevant to each individual country and (ii) DDIs relevant to all three countries. DDIs will be defined as co-dispensed (same day) and concomitantly (±7 days) dispensed.

Results: Descriptive statistics, including DDI prevalence and 95% confidence intervals, will be reported for each country. Prevalence will be pooled and compared across countries using random effects models and meta-regression, where feasible.

Conclusion: The EuroDDI study will develop a harmonised method to measure and compare DDI prevalence across health-related databases in Europe.

References

Wastesson J, Morin L, Tan E, Johnell K . An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018; 17(12):1185-1196. DOI: 10.1080/14740338.2018.1546841. View

Moriarty F, Hardy C, Bennett K, Smith S, Fahey T . Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015; 5(9):e008656. PMC: 4577876. DOI: 10.1136/bmjopen-2015-008656. View

Moura C, Acurcio F, Belo N . Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2010; 12(3):266-72. DOI: 10.18433/j35c7z. View

Iolascon G, Gimigliano F, Orlando V, Capaldo A, Di Somma C, Menditto E . Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res. 2013; 25 Suppl 1:S137-41. DOI: 10.1007/s40520-013-0127-5. View

Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, Calderon-Larranaga A, Poncel-Falco A, Gimeno-Feliu L . Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. Int J Epidemiol. 2018; 47(2):382-384f. PMC: 5913592. DOI: 10.1093/ije/dyx259. View

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T . The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015; 13:74. PMC: 4417329. DOI: 10.1186/s12916-015-0322-7. View

Tragni E, Casula M, Pieri V, Favato G, Marcobelli A, Trotta M . Prevalence of the prescription of potentially interacting drugs. PLoS One. 2013; 8(10):e78827. PMC: 3795676. DOI: 10.1371/journal.pone.0078827. View

Delafuente J . Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003; 48(2):133-43. DOI: 10.1016/j.critrevonc.2003.04.004. View

Hermann M, Carstens N, Kvinge L, Fjell A, Wennersberg M, Folleso K . Polypharmacy and Potential Drug-Drug Interactions in Home-Dwelling Older People - A Cross-Sectional Study. J Multidiscip Healthc. 2021; 14:589-597. PMC: 7955724. DOI: 10.2147/JMDH.S297423. View

10.

Franchi C, Tettamanti M, Pasina L, Djignefa C, Fortino I, Bortolotti A . Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010. Eur J Clin Pharmacol. 2014; 70(4):437-43. DOI: 10.1007/s00228-013-1621-6. View

11.

Roughead E, Kalisch L, Barratt J, Gilbert A . Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol. 2010; 70(2):252-7. PMC: 2911555. DOI: 10.1111/j.1365-2125.2010.03694.x. View

12.

Mallet L, Spinewine A, Huang A . The challenge of managing drug interactions in elderly people. Lancet. 2007; 370(9582):185-191. DOI: 10.1016/S0140-6736(07)61092-7. View

13.

Becker M, Kallewaard M, Caspers P, Visser L, Leufkens H, Stricker B . Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2006; 16(6):641-51. DOI: 10.1002/pds.1351. View

14.

Hughes J, Russo V, Walsh C, Menditto E, Bennett K, Cahir C . Prevalence and Factors Associated with Potential Drug-Drug Interactions in Older Community-Dwelling Adults: A Prospective Cohort Study. Drugs Aging. 2021; 38(11):1025-1037. PMC: 8594274. DOI: 10.1007/s40266-021-00898-8. View

15.

Strandell J, Bate A, Lindquist M, Ralph Edwards I . Drug-drug interactions - a preventable patient safety issue?. Br J Clin Pharmacol. 2007; 65(1):144-6. PMC: 2291271. DOI: 10.1111/j.1365-2125.2007.02981.x. View

16.

Grimes T, Fitzsimons M, Galvin M, Delaney T . Relative accuracy and availability of an Irish National Database of dispensed medication as a source of medication history information: observational study and retrospective record analysis. J Clin Pharm Ther. 2013; 38(3):219-24. DOI: 10.1111/jcpt.12036. View

17.

Steinman M, Miao Y, Boscardin W, Komaiko K, Schwartz J . Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014; 29(10):1379-86. PMC: 4175643. DOI: 10.1007/s11606-014-2924-8. View

18.

Demessine L, Peyro-Saint-Paul L, Gardner E, Ghosn J, Parienti J . Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France. Open Forum Infect Dis. 2019; 6(3):ofz051. PMC: 6440683. DOI: 10.1093/ofid/ofz051. View

19.

Burato S, Leonardi L, Antonazzo I, Raschi E, Ajolfi C, Baraghini M . Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. Front Pharmacol. 2021; 11:624888. PMC: 7898059. DOI: 10.3389/fphar.2020.624888. View

20.

Chen S, Wu S . Deep Q-networks with web-based survey data for simulating lung cancer intervention prediction and assessment in the elderly: a quantitative study. BMC Med Inform Decis Mak. 2022; 22(1):1. PMC: 8725301. DOI: 10.1186/s12911-021-01695-4. View